Cantor Fitzgerald Reaffirms Their Buy Rating on Prothena Corp

By Ryan Adsit

Cantor Fitzgerald analyst William Tanner reiterated a Buy rating on Prothena Corp (NASDAQ: PRTA) yesterday and set a price target of $18. The company’s shares closed yesterday at $14.70, close to its 52-week low of $10.43.

Tanner observed:

“We are reiterating our Overweight rating for PRTA stock and we are raising our PT to $18 from $14 based on our analysis of the potential value of PRTA’s drug discovery platform and management’s recently announced restructuring plan.”

According to, Tanner is a 4-star analyst with an average return of 10.3% and a 57.1% success rate. Tanner covers the Healthcare sector, focusing on stocks such as Synergy Pharmaceuticals Inc, Supernus Pharmaceuticals, and Intra-Cellular Therapies.

Prothena Corp has an analyst consensus of Hold, with a price target consensus of $13.86.

See today’s analyst top recommended stocks >>

The company has a one-year high of $70 and a one-year low of $10.43. Currently, Prothena Corp has an average volume of 1.06M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Prothena Corp. Plc is a late-stage clinical biotechnology company, which research, development and commercialization of therapies in the neuroscience and orphan categories. Its antibody-based product candidates target a potential indications including amyloidosis and Parkinson’s disease.